Clinical Trial Update: Circulating MicroRNA as Biomarker of Cardiotoxicity in Breast Cancer

View source ↗

Summary

A completed clinical trial evaluated circulating microRNA as a biomarker of cardiotoxicity in breast cancer. The study sponsor is West Pomeranian Cancer Center.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: West Pomeranian Cancer Center | Conditions: Breast Cancer | Status: COMPLETED